1924 related articles for article (PubMed ID: 7923244)
1. Enhanced in vivo sensitivity to interferon with in vitro resistant B16 tumor cells in mice.
Fleischmann CM; Stanton GJ; Fleischmann WR
Cancer Immunol Immunother; 1994 Sep; 39(3):148-54. PubMed ID: 7923244
[TBL] [Abstract][Full Text] [Related]
2. Enhanced in vivo sensitivity of in vitro interferon-treated B16 melanoma cells to CD8 cells and activated macrophages.
Fleischmann CM; Stanton GJ; Fleischmann WR
J Interferon Cytokine Res; 1996 Oct; 16(10):805-12. PubMed ID: 8910765
[TBL] [Abstract][Full Text] [Related]
3. Enhanced in vitro macrophage cytotoxicity against interferon-treated B16 melanoma cells.
Fleischmann CM; Fleischmann WR
J Biol Regul Homeost Agents; 1995; 9(4):139-45. PubMed ID: 8844338
[TBL] [Abstract][Full Text] [Related]
4. Effect of murine alpha-, beta-, and gamma-interferons in combination with alpha-difluoromethylornithine, an inhibitor of polyamine biosynthesis, on the tumor growth and metastasis of B16 melanoma and Lewis lung carcinoma in mice.
Sunkara PS; Bowlin TL; Rosenberger AL; Fleischmann WR
J Biol Response Mod; 1989 Apr; 8(2):170-9. PubMed ID: 2499664
[TBL] [Abstract][Full Text] [Related]
5. Resistance to the antiproliferative activity of IFN-alpha: further characterization and demonstration of antagonistic effects of IFN-gamma.
Fleischmann CM; Fleischmann WR
J Biol Regul Homeost Agents; 1991; 5(1):34-42. PubMed ID: 1909084
[TBL] [Abstract][Full Text] [Related]
6. The antitumor effects of interferon-alpha are maintained in mice challenged with a STAT1-deficient murine melanoma cell line.
Badgwell B; Lesinski GB; Magro C; Abood G; Skaf A; Carson W
J Surg Res; 2004 Jan; 116(1):129-36. PubMed ID: 14732359
[TBL] [Abstract][Full Text] [Related]
7. Accelerated tumor development in interferon-treated B6.C-Hyal-1 a mice.
De Maeyer-Guignard J; Lauret E; Eusèbe L; De Maeyer E
Proc Natl Acad Sci U S A; 1993 Jun; 90(12):5708-12. PubMed ID: 8516320
[TBL] [Abstract][Full Text] [Related]
8. B16 melanoma cells exposed in vitro to long-term IFN-alpha treatment (B16 alpha cells) as activators of tumor immunity in mice.
Fleischmann CM; Wu TY; Fleischmann WR
J Interferon Cytokine Res; 1997 Jan; 17(1):37-43. PubMed ID: 9041470
[TBL] [Abstract][Full Text] [Related]
9. In vivo interferon regulatory factor 3 tumor suppressor activity in B16 melanoma tumors.
Duguay D; Mercier F; Stagg J; Martineau D; Bramson J; Servant M; Lin R; Galipeau J; Hiscott J
Cancer Res; 2002 Sep; 62(18):5148-52. PubMed ID: 12234977
[TBL] [Abstract][Full Text] [Related]
10. Enhanced antitumor efficacy in mice by combination treatment with interleukin-1 alpha and interferon-alpha.
Brunda MJ; Wright RB; Luistro L; Harbison ML; Anderson TD; McIntyre KW
J Immunother Emphasis Tumor Immunol; 1994 May; 15(4):233-41. PubMed ID: 8061895
[TBL] [Abstract][Full Text] [Related]
11. Characterization of the mouse IFN-lambda ligand-receptor system: IFN-lambdas exhibit antitumor activity against B16 melanoma.
Lasfar A; Lewis-Antes A; Smirnov SV; Anantha S; Abushahba W; Tian B; Reuhl K; Dickensheets H; Sheikh F; Donnelly RP; Raveche E; Kotenko SV
Cancer Res; 2006 Apr; 66(8):4468-77. PubMed ID: 16618774
[TBL] [Abstract][Full Text] [Related]
12. IFN-alpha 1 gene transfection completely abolishes the tumorigenicity of murine B16 melanoma cells in allogeneic DBA/2 mice and decreases their tumorigenicity in syngeneic C57BL/6 mice.
Kaido T; Bandu MT; Maury C; Ferrantini M; Belardelli F; Gresser I
Int J Cancer; 1995 Jan; 60(2):221-9. PubMed ID: 7829220
[TBL] [Abstract][Full Text] [Related]
13. Antiproliferative effects of interferons on human melanoma cells in the human tumor colony-forming assay.
Schiller JH; Willson JK; Bittner G; Wolberg WH; Hawkins MJ; Borden EC
J Interferon Res; 1986 Dec; 6(6):615-25. PubMed ID: 2437222
[TBL] [Abstract][Full Text] [Related]
14. Immunization with interleukin-2/interferon-gamma double cytokine-secreting allogeneic fibroblasts prolongs the survival of mice with melanoma.
Kim TS; Xu WS; Sun T; Cohen EP
Melanoma Res; 1995 Aug; 5(4):217-27. PubMed ID: 7496156
[TBL] [Abstract][Full Text] [Related]
15. Enhancing in vivo tumorigenicity of B16 melanoma by overexpressing interferon regulatory factor-2: resistance to endogenous IFN-gamma.
Yim JH; Wu SJ; Lowney JK; Vander Velde TL; Doherty GM
J Interferon Cytokine Res; 1999 Jul; 19(7):723-9. PubMed ID: 10454342
[TBL] [Abstract][Full Text] [Related]
16. In vitro comparative study of the antitumor effects of human interferon-alpha, beta and gamma on the growth and invasive potential of human melanoma cells.
Horikoshi T; Fukuzawa K; Hanada N; Ezoe K; Eguchi H; Hamaoka S; Tsujiya H; Tsukamoto T
J Dermatol; 1995 Sep; 22(9):631-6. PubMed ID: 8537547
[TBL] [Abstract][Full Text] [Related]
17. Chronopharmacology of antitumor effect induced by interferon-beta in tumor-bearing mice.
Takane H; Ohdo S; Yamada T; Yukawa E; Higuchi S
J Pharmacol Exp Ther; 2000 Aug; 294(2):746-52. PubMed ID: 10900256
[TBL] [Abstract][Full Text] [Related]
18. Difference of interferon-α and interferon-β on melanoma growth and lymph node metastasis in mice.
Roh MR; Zheng Z; Kim HS; Jeung HC; Rha SY; Chung KY
Melanoma Res; 2013 Apr; 23(2):114-24. PubMed ID: 23358428
[TBL] [Abstract][Full Text] [Related]
19. Interferon gamma induces lung colonization by intravenously inoculated B16 melanoma cells in parallel with enhanced expression of class I major histocompatibility complex antigens.
Taniguchi K; Petersson M; Höglund P; Kiessling R; Klein G; Kärre K
Proc Natl Acad Sci U S A; 1987 May; 84(10):3405-9. PubMed ID: 3106968
[TBL] [Abstract][Full Text] [Related]
20. Ly-6A/E gene is widely expressed among transformed nonhematopoietic cells. Autocrine modulation by interferon.
Lollini PL; Landuzzi L; Nicoletti G; de Giovanni C; Giovarelli M; Lalli E; Facchini A; Nanni P
Anticancer Res; 1992; 12(6B):2245-52. PubMed ID: 1295472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
